ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the first quarter ended March 31, 2015 on Thursday, May 14, 2015.
InSite Vision management will host a conference call that day beginning at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss first quarter 2015 financial results and to review recent accomplishments and upcoming milestones.
Analysts and investors can participate in the conference call by dialing 888-713-4217 for domestic callers and +1 617-213-4869 for international callers using the pass code 43350327. A telephone replay will be available following the conclusion of the call by dialing 888-286-8010 for domestic callers and +1 617-801-6888 for international callers using the pass code 95470362.
The conference call will be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties are encouraged to pre-register here.
About InSite Vision
InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite® 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn Inc.; and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International. InSite Vision is advancing AzaSite Plus™, a novel ophthalmic therapeutics through Phase 3 clinical studies for the treatment of eye infections. The company is preparing two NDAs for commercial approval by the U.S. Food & Drug Administration (FDA): BromSite for the treatment of inflammation and prevention of pain associated with cataract surgery, which is ready for FDA submission; and DexaSite™ for the treatment of blepharitis. For further information on InSite Vision, please visit www.insitevision.com.
AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
AzaSite Plus™, BromSite™ and DexaSite™ are trademarks of InSite Vision Incorporated.
Besivance® is a registered trademark of Bausch + Lomb Incorporated.